Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05477576 | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | PHASE3 | RECRUITING | 288 | — | — | Mar 1, 2022 | Jul 1, 2028 | Jan 19, 2026 | - | — |
| Name | Type | Description |
|---|---|---|
| RYZ101 | DRUG | RP3D as determined in Phase 1b |
| Everolimus | DRUG | Everolimus |
| Sunitinib | DRUG | Sunitinib |
| Octreotide | DRUG | High-dose octreotide |
| Lanreotide | DRUG | Lanreotide |